An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment

Lung cancer is the leading cause of cancer-related death worldwide. Its late diagnosis and consequently poor survival make necessary the search for new therapeutic targets. The mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) is overexpressed in lung cancer and correlates with poo...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-04, Vol.15 (4), p.1273
Main Authors: Carrión-Marchante, Rebeca, Pinto-Díez, Celia, Klett-Mingo, José Ignacio, Palacios, Esther, Barragán-Usero, Miriam, Pérez-Morgado, M Isabel, Pascual-Mellado, Manuel, Alcalá, Sonia, Ruiz-Cañas, Laura, Sainz, Jr, Bruno, González, Víctor M, Martín, M Elena
Format: Article
Language:English
Subjects:
Antibodies
Antimitotic agents
Antineoplastic agents
antitumor
aptamer
Breast cancer
Cancer therapies
Care and treatment
Cell cycle
Clinical trials
Cytotoxicity
Dosage and administration
Growth factors
Health aspects
Kinases
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Mitogen-activated protein kinases
MNK1
non-small cell lung cancer
NSCLC
Penicillin
Prognosis
Proteins
Risk factors
Sodium
Testing
therapeutic target
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading cause of cancer-related death worldwide. Its late diagnosis and consequently poor survival make necessary the search for new therapeutic targets. The mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) is overexpressed in lung cancer and correlates with poor overall survival in non-small cell lung cancer (NSCLC) patients. The previously identified and optimized aptamer from our laboratory against MNK1, apMNKQ2, showed promising results as an antitumor drug in breast cancer in vitro and in vivo. Thus, the present study shows the antitumor potential of apMNKQ2 in another type of cancer where MNK1 plays a significant role, such as NSCLC. The effect of apMNKQ2 in lung cancer was studied with viability, toxicity, clonogenic, migration, invasion, and in vivo efficacy assays. Our results show that apMNKQ2 arrests the cell cycle and reduces viability, colony formation, migration, invasion, and epithelial-mesenchymal transition (EMT) processes in NSCLC cells. In addition, apMNKQ2 reduces tumor growth in an A549-cell line NSCLC xenograft model. In summary, targeting MNK1 with a specific aptamer may provide an innovative strategy for lung cancer treatment.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15041273